Limits...
Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.

Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K - Stroke (2015)

Bottom Line: A model-based cost-utility analysis was performed using a lifetime horizon.A Markov model was constructed and populated with probabilities, outcomes, and cost data from published sources, including 1-way and probabilistic sensitivity analysis.This is an important factor for consideration in deciding whether to commission this intervention.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Stroke Medicine, Imperial College Healthcare NHS Trust, London, UK (J.G., D.A.); Department of Applied Health Research, University College London, London, UK (E.P., S.M.); Department of Market Access, Pricing and Outcomes Research, Boehringer Ingelheim Ltd, Bracknell, Berks, UK (T.S.); and Imaging Department, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK (K.L.).

Show MeSH

Related in: MedlinePlus

Cost-effectiveness acceptability curves showing the probability that each option is cost-effective at different values of the willingness to pay for a quality-adjusted life years (QALY). In the United Kingdom, the lower and upper limit of the maximum willingness to pay for a QALY are $33 000 (£20 000) and $49 500 (£30 000) respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4542565&req=5

Figure 2: Cost-effectiveness acceptability curves showing the probability that each option is cost-effective at different values of the willingness to pay for a quality-adjusted life years (QALY). In the United Kingdom, the lower and upper limit of the maximum willingness to pay for a QALY are $33 000 (£20 000) and $49 500 (£30 000) respectively.

Mentions: A probabilistic sensitivity analysis was also undertaken to determine the impact of the uncertainty surrounding the model input parameters (see Table III in the online-only Data Supplement).27 In Table 1, we describe the distribution assigned to each parameter value.42 A random value from the corresponding distribution was selected. This generated an estimate of the mean cost and mean QALY and the NMB associated with each treatment. This was repeated 10 000 times, and the results for each simulation were noted. The proportion of times either treatment (thrombectomy or IV-tPA) had the highest NMB was calculated for a range of values of the willingness to pay for a QALY. The results are summarized using cost-effectiveness acceptability curves in Figure 2. The mean cost, QALYs, and NMB for each treatment were calculated from the 10 000 simulations; these are probabililistic results (Figure 3; online-only Data Supplement).


Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.

Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K - Stroke (2015)

Cost-effectiveness acceptability curves showing the probability that each option is cost-effective at different values of the willingness to pay for a quality-adjusted life years (QALY). In the United Kingdom, the lower and upper limit of the maximum willingness to pay for a QALY are $33 000 (£20 000) and $49 500 (£30 000) respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4542565&req=5

Figure 2: Cost-effectiveness acceptability curves showing the probability that each option is cost-effective at different values of the willingness to pay for a quality-adjusted life years (QALY). In the United Kingdom, the lower and upper limit of the maximum willingness to pay for a QALY are $33 000 (£20 000) and $49 500 (£30 000) respectively.
Mentions: A probabilistic sensitivity analysis was also undertaken to determine the impact of the uncertainty surrounding the model input parameters (see Table III in the online-only Data Supplement).27 In Table 1, we describe the distribution assigned to each parameter value.42 A random value from the corresponding distribution was selected. This generated an estimate of the mean cost and mean QALY and the NMB associated with each treatment. This was repeated 10 000 times, and the results for each simulation were noted. The proportion of times either treatment (thrombectomy or IV-tPA) had the highest NMB was calculated for a range of values of the willingness to pay for a QALY. The results are summarized using cost-effectiveness acceptability curves in Figure 2. The mean cost, QALYs, and NMB for each treatment were calculated from the 10 000 simulations; these are probabililistic results (Figure 3; online-only Data Supplement).

Bottom Line: A model-based cost-utility analysis was performed using a lifetime horizon.A Markov model was constructed and populated with probabilities, outcomes, and cost data from published sources, including 1-way and probabilistic sensitivity analysis.This is an important factor for consideration in deciding whether to commission this intervention.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Stroke Medicine, Imperial College Healthcare NHS Trust, London, UK (J.G., D.A.); Department of Applied Health Research, University College London, London, UK (E.P., S.M.); Department of Market Access, Pricing and Outcomes Research, Boehringer Ingelheim Ltd, Bracknell, Berks, UK (T.S.); and Imaging Department, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK (K.L.).

Show MeSH
Related in: MedlinePlus